VolitionRx Limited to Present at 9th Annual Biotech Showcase Conference

NAMUR, Belgium, Dec. 28, 2016 /PRNewswire/ -- VolitionRx Limited (NYSE MKT: VNRX) today announced that it will present at the 9th Annual Biotech Showcase Conference being held from January 9-11, 2017 in San Francisco, CA.

At the Biotech Showcase, Cameron Reynolds, Chief Executive Officer of Volition, will provide an update on Volition's business, clinical, regulatory and operational milestones, as well as the Company's recently announced product launch of its Nu.QTM Colorectal Cancer Screening Triage Test.

Event:

9th Annual Biotech Showcase Conference

Date:

Tuesday, January 10, 2017

Time:

8:30 AM Pacific Time

Location:

Room 8 (Ballroom Level), Hilton San Francisco Union Square Hotel,  San Francisco, CA

The presentation will be webcast live and will be available on the Investor Relations page of Volition's website at http://ir.volitionrx.com/. The webcast will remain available for 90 days following the presentation.

About Volition

Volition is a life sciences company focused on developing diagnostic tests for cancer. The tests are based on the science of Nucleosomics®, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid -- an indication that disease is present.

Volition's goal is to make the tests as easy and simple to use, for both patients and doctors, as existing diabetic and cholesterol blood tests. Volition's research and development activities are currently centered in Belgium as the company focuses on bringing its diagnostic products to market first in Europe, then in the U.S. and ultimately, worldwide.

For more information about Volition, visit Volition's website (http://www.volitionrx.com) or connect with us via:

Twitter: https://twitter.com/volitionrx 
LinkedIn: https://www.linkedin.com/company/volitionrx
Facebook: https://www.facebook.com/VolitionRx/
YouTube: https://www.youtube.com/user/VolitionRx

The contents found at Volition's website address, Twitter, LinkedIn, Facebook, and YouTube are not incorporated by reference into this document and should not be considered part of this document.  The addresses for Volition's website, Twitter, LinkedIn, Facebook, and YouTube are included in this document as inactive textual references only.

Media / Investor Contacts

Louise Day, Volition

L.day@volitionrx.com

+44 (0)7557 774620

Scott Powell, Volition

S.powell@volitionrx.com

+1 (646) 650 1351

Tirth Patel, Edison Advisors

tpatel@edisongroup.com

+1 (646) 653 7035

Rachel Carroll, Edison Advisors

rcarroll@edisongroup.com

+44 (0)20 3077 5711

Sarah Roberts, Vane Percy & Roberts

sarah@vanepercy.com

+44 (0)1737 821 890


Nucleosomics®, NuQ®, Nu.QTM and HyperGenomics® and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release are the property of their respective owners.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/volitionrx-limited-to-present-at-9th-annual-biotech-showcase-conference-300382614.html

SOURCE VolitionRx Ltd.